Clinical characteristics, risk factors, and medical treatment of 561 patients with peripheral arterial disease followed in an academic vascular surgery clinic

Cardiology in Review

Volumn 13, Issue 2, 2005, Pages 108-110

  Sukhija, Rishi ^b   Yalamanchili, Kiran ^b   Aronow, Wilbert S ^a   Kakar, Priyanka ^b   Babu, Sateesh ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Antiplatelet drugs; Cilostazol; Coronary artery disease; Intermittent claudication; Peripheral arterial disease; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PENTOXIFYLLINE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERIOSCLEROSIS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MEDICAL AUDIT; MIDDLE AGED; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; TETRAZOLES;

EID: 14044254794     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000128729.41155.a6     Document Type: Article

References (19)

1. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age. Am J Cardiol. 1994;74:64-65.
2. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:1255-1256.
3. Sukhija R, Yalamanchili K, Aronow WS. Prevalence of left main coronary artery disease, of 3-vessel or 4-vessel coronary artery disease, and of obstructive coronary artery disease in patients with and without peripheral arterial disease undergoing coronary angiography for suspected coronary artery disease. Am J Cardiol. 2003;92:304-305.
4. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
5. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality: the Whitehall study. Circulation. 1990;82:1925-1931.
6. Aronow WS, Ahn C, Mercando AD, et al. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction. Am J Cardiol. 1992;69:137-139.
7. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333-336.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
11. Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90:789-791.
12. Aronow WS, Nayak D, Woodworth S, et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at 6 months and at 1 year after treatment. Am J Cardiol. 2003;92:711-712.
13. Smith SC Jr, Blair SN, Bonow RO, et al. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38:1581-1583.
14. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol. 2001;87:1284-1286.
15. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-530.
16. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003; 289:2560-2572.
17. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
19. Aronow WS, Ahn C. Reduction of coronary events by aspirin in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL. Heart Dis. 2002;4:159-161.